• By Fierce Biotech   -   May 11, 2021

    EXPELLING CANCER BY SQUEEZING OUT ROGUE CELLS

    Expelling cancer by squeezing out rogue cells aliu Wed, 05/05/2021 - 08:01

    Cancer
  • By Fierce Biotech   -   May 11, 2021

    CHEMOCENTRYX'S STOCK SINKS AS FDA FLAGS ISSUES WITH PIVOTAL DATA

    ChemoCentryx's stock sinks as FDA flags issues with pivotal data ntaylor Wed, 05/05/2021 - 08:15

  • By Fierce Biotech   -   May 11, 2021

    NOVARTIS LOSES 2ND ONCOLOGY R&D EXEC AS HAMMERMAN LEAVES THROUGH THE DOOR LEFT OPEN BY ENGELMAN

    Novartis loses 2nd oncology R&D exec as Hammerman leaves through the door left open by Engelman badams Tue, 05/04/2021 - 04:00

    R&D
  • By Fierce Biotech   -   May 11, 2021

    LILLY TAKES VARIANT-BUSTING COVID-19 ANTIBODY INTO THE CLINIC

    Lilly takes variant-busting COVID-19 antibody into the clinic ntaylor Tue, 05/04/2021 - 07:55

    Clinical
  • By Fierce Biotech   -   May 11, 2021

    PFIZER HALTS BCMA TRIAL AMID SAFETY WOES, HIT BY DMD DELAY

    Pfizer halts BCMA trial amid safety woes, hit by DMD delay ntaylor Tue, 05/04/2021 - 08:57

  • By Fierce Biotech   -   May 11, 2021

    HOW NEW 'LUNG-ON-A-CHIP' MODELS FROM HARVARD ARE ADVANCING COVID-19 DRUG DISCOVERY

    How new 'lung-on-a-chip' models from Harvard are advancing COVID-19 drug discovery arlene.weintraub Mon, 05/03/2021 - 08:55

    Drugs, Drug, Discovery
  • By Fierce Biotech   -   May 11, 2021

    ASTELLAS QUIETLY CUTS CYTOKINETICS R&D PACT AS $450M-PLUS IN BIOBUCKS GOES UP IN SMOKE

    Astellas quietly cuts Cytokinetics R&D pact as $450M-plus in biobucks goes up in smoke badams Mon, 05/03/2021 - 04:45

    R&D
  • By Fierce Biotech   -   May 11, 2021

    ACERAGEN BAGS ENZYVANT DRUG AND $35M, PLOTS FAST PATH TO MARKET

    Aceragen bags Enzyvant drug and $35M, plots fast path to market ntaylor Mon, 05/03/2021 - 07:56

    Drugs, Drug
  • By Fierce Biotech   -   May 11, 2021

    ASTRAZENECA'S CANCER R&D EXEC FERTÉ JOINS RELAY TO RUN ITS LEAD ASSET AS ANOTHER BLUEBIRD EXEC JUMPS SHIP

    AstraZeneca's cancer R&D exec Ferté joins Relay to run its lead asset as another bluebird exec jumps ship badams Mon, 05/03/2021 -...

    R&D, Cancer
  • By Fierce Biotech   -   May 11, 2021

    AVROBIO PLANS HEAD-TO-HEAD FABRAZYME TRIAL AFTER FDA CHANGES PATH TO MARKET

    Avrobio plans head-to-head Fabrazyme trial after FDA changes path to market ntaylor Mon, 05/03/2021 - 08:41

  • By Fierce Biotech   -   May 11, 2021

    CHUTES & LADDERS-LILLY VET BILENKER AND NOVARTIS' ENGELMAN UNITE TO FORGE NEW CANCER BIOTECH

    Chutes & Ladders-Lilly vet Bilenker and Novartis' Engelman unite to forge new cancer biotech fkansteiner Thu, 04/29/2021 - 15:50

    Cancer, Biotech, BioTech
  • By Fierce Biotech   -   May 11, 2021

    WEREWOLF THERAPEUTICS HOWLS ONTO THE NASDAQ WITH $120M IPO

    Werewolf Therapeutics howls onto the Nasdaq with $120M IPO aalidrus Fri, 04/30/2021 - 09:25

    Therapeutics, NASDAQ
  • By Fierce Biotech   -   May 11, 2021

    NOVAVAX HANDED AN EXTRA $147M FROM LEGACY WARP SPEED PROGRAM AS SPOTLIGHT SHINES BRIGHTER

    Novavax handed an extra $147M from legacy Warp Speed program as spotlight shines brighter badams Fri, 04/30/2021 - 06:36

  • By Fierce Biotech   -   May 11, 2021

    CRISPR SCREEN POINTS TO SPINAL REPAIR PATHWAY IN ZEBRAFISH

    CRISPR screen points to spinal repair pathway in zebrafish arlene.weintraub Fri, 04/30/2021 - 07:49

  • By Fierce Biotech   -   May 11, 2021

    CARA'S STOCK TANKS AS ATOPIC DERMATITIS PHASE 2 MISSES ENDPOINT

    Cara's stock tanks as atopic dermatitis phase 2 misses endpoint ntaylor Fri, 04/30/2021 - 08:22

  • By Fierce Biotech   -   May 11, 2021

    ASTRAZENECA DROPS BCMA DRUG AFTER SEEING EARLY CLINICAL DATA

    AstraZeneca drops BCMA drug after seeing early clinical data ntaylor Fri, 04/30/2021 - 06:22

    Drugs, Drug, Clinical
  • By Fierce Biotech   -   May 11, 2021

    IS COMBINED RECOGNITION THE SOLUTION FOR CAR-T THERAPY AGAINST GLIOBLASTOMA, OTHER SOLID TUMORS?

    Is combined recognition the solution for CAR-T therapy against glioblastoma, other solid tumors? aliu Thu, 04/29/2021 - 08:49

    Therapies
  • By Fierce Biotech   -   May 11, 2021

    ADCENDO RAISES €51M SERIES A ROUND TO PURSUE 'IDEAL' ADC TARGET

    Adcendo raises €51M series A round to pursue 'ideal' ADC target ntaylor Thu, 04/29/2021 - 08:05

  • By Fierce Biotech   -   May 11, 2021

    FLAGSHIP'S REPERTOIRE ALLIES WITH YALE TO IDENTIFY DRIVERS OF MULTIPLE SCLEROSIS

    Flagship's Repertoire allies with Yale to identify drivers of multiple sclerosis ntaylor Thu, 04/29/2021 - 08:38

  • By Fierce Biotech   -   May 11, 2021

    IN A FIRST, FDA ISSUES A SERIOUS REBUKE FOR TRIAL DATA DELAY AS IT LOOKS TO GET TOUGH

    In a first, FDA issues a serious rebuke for trial data delay as it looks to get tough badams Thu, 04/29/2021 - 03:51